Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: a systematic review and meta-analysis of randomized controlled trials

Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now considered as key players in the treatment of type 2 diabetes mellitus (T2DM). The purpose of this meta-analysis was to provide precise effect estimates regarding the safety and efficacy of the addition of a GLP-1RA on top of SGLT-2i treatment.

Source: Diabetes Research and Clinical Practice - November 12, 2019 Category: Endocrinology Authors: Dimitrios Patoulias, Konstantinos Stavropoulos, Konstantinos Imprialos, Alexandra Katsimardou, Maria-Styliani Kalogirou, Konstantinos Koutsampasopoulos, Ioanna Zografou, Christodoulos Papadopoulos, Asterios Karagiannis, Michael Doumas Source Type: research